Discussion
A single injection of the next-generation drug rademikibart markedly cut the rate and impact of acute exacerbations among adults with chronic obstructive pulmonary disease (COPD) over one month versus a placebo in a global clinical trial. That’s according to new data announced by therapy developer Connect Biopharma, which…